EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study

Edward C Portillo, Michael Pollack, Inyoung Lee, Kainan Sun, Xiaohui Zhao iD, Lisa Kruse, Norbert Feigler, Sushma Patel, Aimee M Near

Therapeutic Advances in Respiratory Disease · 2023

DOI: 10.1177/17534666231164534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2023. Verfasst von Edward C Portillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Wisconsin, Madison, WI, USA. Hauptthemen laut MEDLINE: Bronchodilator Agents, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

A twice-daily single inhaler triple therapy consisting of budesonide/glycopyrrolate/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective of this AURA study is to describe patient characteristics, exacerbation and treatment history, and healthcare resource utilization (HCRU) before BGF initiation to better inform treatment decisions for prescribers.

Methods

This retrospective cohort study leveraged data of all payer types from IQVIA’s Longitudinal Prescription Data (LRx) linked to Medical Data (Dx). Patients with COPD who had ⩾1 LRx claim for BGF between 1 October 2020 and 30 September 2021 were included. The date of first BGF claim was the index date. Patient demographic and clinical characteristics, history of COPD exacerbation or related event, treatment history, and HCRU were assessed during the 12 months before index (baseline).

Results

We identified 30,339 patients with COPD initiating BGF (mean age: 68.2 years; 57.1% female; 67.6% Medicare). Unspecified COPD (J44.9; 74.0%) was the most commonly coded COPD phenotype. The most prevalent respiratory conditions/symptoms were dyspnea (50.8%), lower respiratory tract infection (25.3%), and sleep apnea (19.0%). Uncomplicated hypertension (58.8%), dyslipidemia (43.9%), cardiovascular disease (41.4%), and heart failure (19.9%) were the most prevalent nonrespiratory conditions. During the 12-month baseline, 57.9% of patients had evidence of a COPD exacerbation or related event, and 14.9% had ⩾1 COPD-related emergency department (ED) visit; 21.0% of patients had evidence of prior triple therapy use, while 54.3% had ⩾1 oral corticosteroid (OCS) fill. Among OCS users, 29.9% had cumulative exposures >1000 mg [median [Q1–Q3] exposure: 520 (260–1183) mg].

Conclusion

This real-world data analysis indicates that BGF is being initiated in patients with COPD experiencing symptoms and exacerbations despite current therapy, and among patients who have various chronic comorbidities, most often cardiopulmonary-related.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAgedHumansFemaleUnited StatesMaleFormoterol FumarateGlycopyrrolateRetrospective StudiesDrug CombinationsMetered Dose InhalersMedicareBudesonideAdministration, Inhalation

Stichwörter der Autor:innen

budesonide/glycopyrrolate/formoterolchronic obstructive pulmonary diseaseexacerbationsreal-world datasingle-inhaler triple therapy

Substanzen

Bronchodilator AgentsFormoterol FumarateGlycopyrrolateDrug CombinationsBudesonide

Autor:innen und Institutionen

  • School of Pharmacy, University of Wisconsin, Madison, WI, USA.
  • US Medical, BioPharmaceuticals, AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850, USA.
  • IQVIA, Durham, NC, USA.
  • US Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.

ORCID-Profile: Xiaohui Zhao

Förderung

  • AstraZeneca

Zitieren

APA

Portillo, E. C., Pollack, M., Lee, I., Sun, K., Zhao, X., Kruse, L., Feigler, N., Patel, S., & Near, A. M. (2023). Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231164534

Vancouver

Portillo EC, Pollack M, Lee I, Sun K, Zhao X, Kruse L, et al. Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study. Therapeutic Advances in Respiratory Disease. 2023. doi:10.1177/17534666231164534

BibTeX
@article{Portillo2023,
  author = {Portillo, Edward C and Pollack, Michael and Lee, Inyoung and Sun, Kainan and Zhao, Xiaohui and Kruse, Lisa and Feigler, Norbert and Patel, Sushma and Near, Aimee M},
  title = {Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2023},
  doi = {10.1177/17534666231164534}
}
Kostenlos starten →